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A B S T R A C T
Purpose
Massively parallel sequencing allows simultaneous testing ofmultiple genes associatedwith cancer
susceptibility. Guidelines are available for variant classification; however, interpretation of these
guidelines by laboratories and providers may differ and lead to conflicting reporting and, potentially,
to inappropriate medical management. We describe conflicting variant interpretations between
Clinical Laboratory Improvement Amendments–approved commercial clinical laboratories, as re-
ported to the Prospective Registry of Multiplex Testing (PROMPT), an online genetic registry.
Methods
Clinical data and genetic testing resultswere gathered from1,191 individuals tested for inherited cancer
susceptibility and self-enrolled in PROMPT between September 2014 and October 2015. Overall, 518
participants (603 genetic variants) had a result interpreted bymore than one laboratory, including at least
one submitted to ClinVar, and these were used as the final cohort for the current analysis.
Results
Of the 603 variants, 221 (37%) were classified as a variant of uncertain significance (VUS), 191 (32%) as
pathogenic, and 34 (6%) as benign. The interpretation differed among reporting laboratories for 155 (26%).
Conflicting interpretationsweremost frequently reported forCHEK2 andATM, followed byRAD51C, PALB2,
BARD1,NBN,andBRIP1. Amongall participants, 56of518 (11%)hadavariantwithconflicting interpretations
ranging from pathogenic/likely pathogenic to VUS, a discrepancy that may alter medical management.
Conclusions
Conflicting interpretation of genetic findings from multiplex panel testing used in clinical practice is
frequent and may have implications for medical management decisions.
J Clin Oncol 34:4071-4078. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Advances in next-generation sequencing tech-
nology have led to the development of multiplex
panel testing for themolecular diagnosis of inherited
cancer susceptibility. Commercially available panels
differ in their exact composition but usually include
moderate-penetrance and high-penetrance genes
(with mutations reported in the literature to be
associated with a relative risk [RR] of cancer between
2 and 5, or greater than 5, respectively). Genes in
which mutations are associated with susceptibility to
inherited cancer have been rapidly incorporated into
these panels, often before robust evidence of the
magnitude of the association is known. For some
genes, the relatively low prevalence of mutations
makes it difficult to obtain reliable estimates of the
associated cancer risk.1
Variants of uncertain significance are fre-
quent in panel testing and can be challenging to
resolve. Despite the availability of public databases
for sharing genetic variants, the development of
prediction models based on protein structure and
function, and the potential for laboratory-based
functional analyses to determine the pathogenicity
of some variants, discordant interpretation of the
clinical pathogenicity of variants remains a frequent
problem.2-4 Different standardized classification
systems for interpretation of sequence-based results
have been developed.5,6 The ClinVar database7,8 is
a publicly available database that has allowed clinical
laboratories to submit their identified variants and
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share their interpretation. All accessions of the same genetic variant
provided by different submitters are maintained in ClinVar, which
allows tracking of the changes and sharing of the evidence used for
interpretation. However, submission to ClinVar is voluntary and not
all laboratories choose to submit data. Moreover, resolution of the
diverse submissions is a voluntary activity for experts and a Herculean
task. From a clinical perspective, it is relevant to quantitate the fre-
quencies and describe the patterns of variants with conflicting in-
terpretations, particularly those thatmay impactmedicalmanagement.
Unrelated individuals or even members from the same family
with the same genetic variant tested by different clinical labo-
ratories may be given a different clinical assessment of variant
pathogenicity. The ordering provider may not be aware that a dif-
ferent laboratory testing a patient’s relative has provided a different
interpretation. It is crucial to identify variants with conflicting in-
terpretations among laboratories, the frequencies and types of
discrepancies, and the underlying reasons for these discrepancies to
enable specific guidance for variant curation and to increase the
consistency of variant interpretation among the laboratories.
Here, we describe the frequencies and types of genetic findings
with conflicting interpretations in non-BRCA genes tested as
part of panels assembled by Clinical Laboratory Improvement
Amendments–approved commercial laboratories. Data were col-
lected from individuals who underwent clinical testing and en-
rolled in a prospective registry. This registry includes patients with
results from some commercial laboratories that currently do not
deposit data in ClinVar.
PATIENTS AND METHODS
Overall, 1,191 individuals tested for cancer susceptibility genes as part of
commercial multiplex panels self-enrolled in the ongoing Prospective
Registry of Multiplex Testing (PROMPT) between September 1, 2014, and
September 30, 2015, the period for which data were ascertained for this
analysis.
The PROMPT registry partnered with several clinical laboratories,
including Ambry Genetics, Color Genomics, GeneDx, Invitae, Myriad
Genetics, Pathway Genomics, and Quest Diagnostics, to recruit individuals
who had undergone genetic panel testing and had at least one variant in
their report. Participating laboratories advertised PROMPT within the
packet of test report forms sent to individuals. Health-care providers also
were educated about PROMPT at academic and industry meetings, and
through e-mails. An informational Web site and video were created for
participants and providers. An informational article was communicated
via the Dr Susan Love Research Foundation e-newsletter to individuals
enrolled in the Army of Women. Some participants found the study di-
rectly through Internet.
An enrollment site for PROMPTwas built on a platform maintained
by a partner organization, PatientCrossroads. To enroll, participants
created an account with PatientCrossroads and consented to participate in
an online genetic registry in either an identifiable (contact information
available to research team) or de-identified (contact information not
available to research team) manner. All participants completed the baseline
questionnaire with personal and family cancer history of cancer, genetic
testing, and demographics. Participants were given the opportunity to
upload their genetic testing report to the PatientCrossroads portal or to
send it directly to PROMPT registry staff.
From the initial 1,191 participants assessed for eligibility, individuals
considered for this analysis were required to have verifiable genetic data by
PROMPT staff (ie, a copy of a test report submitted, or a detailed self-
reported test result in the registry that was found in ClinVar). Participants
who had undergone tumor testing, who did not have any genetic findings,
or whose unique finding was a BRCA result, were excluded (n = 112), as
were individuals with self-reported results for which a ClinVar submission
or test report was not available for confirmation (n = 410). From the 669
remaining participants, 518 (43%) had results interpreted by more than
one laboratory (including at least one in ClinVar) or findings with multiple
submissions reported in ClinVar, and these participants were used as the
final cohort for the current analysis (Fig 1). Because commercial labo-
ratories are not required to submit to ClinVar, if there were known dif-
ferences in classification of a genetic test result among laboratories
observed through reporting in the PROMPT registry, then this result was
classified as a conflicting interpretation of pathogenicity. That is, a patient
may have provided a report from a non-ClinVar submitting laboratory and
the same finding may have been entered into ClinVar by another
laboratory.
All genetic test results were checked in the ClinVar public archive
(http://www.ncbi.nlm.nih.gov/clinvar/) and their clinical significance was
assigned according to the submissions by different laboratories through
clinical testing or submissions from research and literature curation. In
ClinVar, if differences in interpretation among submitters are observed, the
genetic test results are classified as conflicting interpretation of patho-
genicity.7 A search for any update in reclassification was performed at the
time of data analysis lock, with no change. Descriptive statistics were used
to describe the study population.
RESULTS
Overall, 518 participants enrolled into PROMPT were considered
eligible for this analysis. Their median age was 52 years (range,
44-61 years) and 95% were female. Overall, 427 (82%) were
white, and 350 (68%) had a cancer diagnosis, mostly breast cancer
(n = 188; 36%). Thirty-one percent had multiple primary tumors.
A total of 419 participants (81%) reported being invited into
PROMPT by their health-care provider or by the laboratory where
the testing had been performed (Table 1).
These 518 participants reported 603 genetic variants with
multiple interpretations by several commercial laboratories and/or
submissions to ClinVar. Of the 518 participants included in this
analysis, 165 provided information from testing done in a labo-
ratory that does not submit to ClinVar. The most frequent gene
with sequence alterations reported through PROMPTwas CHEK2
(n = 117), followed by ATM (n = 105) (Fig 2).
Regarding the type of results according to their clinical in-
terpretation in ClinVar, 220 (36%) were consistently classified as
VUS, 191 (32%) as pathogenic/likely pathogenic, and 34 (6%) as
benign/likely benign, while 155 (26%) were classified as conflicting
interpretation. Among these 155, 26% of them were in CHEK2;
20% in ATM; 8% in RAD51C; 7% in PALB2; 5% in BARD1; 4% in
NBN and APC; 3% in RAD50, PMS2, TP53, and MUTYH; 2% in
BRIP1 and FANCC; and the remainder were distributed among the
other genes at approximately 1% each (Fig 3). Of the 155 dis-
cordant findings, 56 (36%) were reported as pathogenic/likely
pathogenic by at least one laboratory but not by all laboratories
(ie, clinically significant; Table 2).
Of 117 findings with multiple interpretations for CHEK2, 41
(35%) were conflicting, and the majority (n = 36; 88%) would be
characterized as clinically significant. Eighteen were c.470T.C
(p.Ile157T) variant and 12 were c.1283C.T (p.Ser428Phe), both
classified as either pathogenic/likely pathogenic or as VUS
(Table 3). Other variants in this gene with a conflicting
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interpretation between pathogenic/likely pathogenic or VUS are
described in Table 2. In addition, 32 of 105 variants (30%) in the
ATM gene with multiple submissions were classified as conflicting.
However, all of these ATM variants ranged from benign/likely
benign or VUS (Appendix Fig A1, online only; Table 2) and,
therefore, should not alter medical management. In PALB2, nine of
49 findings (18%) reported with multiple submissions were
conflicting; one, c.3113G.A (p.Trp1038Ter), which was reported
three times, was classified as either pathogenic or VUS, and the
remainder were interpreted as either benign or VUS. In BRIP1,
three of 33 findings (9%) were discordant; one of them was re-
ported twice [c.139C.G (p.Pro47Ala)] and was classified as either
likely pathogenic or VUS. In RAD51C, 13 of 26 (50%) findings
(50%) were conflicting. Twelve of these findings corresponded to
the variant c.790G.A (p.Gly264Ser), which was submitted as
either benign or VUS, and one, the c.1026+5_1026+7delGTA
variant, was interpreted as both likely pathogenic and VUS. In the
NBN, six of 20 findings (30%) reported were conflicting. Two of
them, c.511A.G (p.Ile171Val) and c.643C.T (p.Arg215Trp),
were reported twice each, and had a two-step difference in con-
flicting interpretation in ClinVar (pathogenic, VUS, benign/likely
benign). Other genes with conflicting interpretation are listed in
Table 2.
DISCUSSION
One quarter of the clinical genetic results from commercially
available multiplex cancer panels and reported at the PROMPT
registry had conflicting interpretations within ClinVar. Most of the
variants with conflicting interpretations were in CHEK2, followed
by ATM, RAD51C, and PALB2. Many conflicting interpretations
are of low clinical significance because the discrepancy ranged
between an interpretation of benign/likely benign or VUS;
therefore, medical management should default to personal and
family history. However, the identification of a VUS can cause
a great deal of uncertainty for patients and providers alike and
increase the risk for inappropriate medical management.5 For
example, it is inappropriate to recommend oophorectomy based
on a VUS finding alone. Of greater concern, 36% of conflicting
results appeared to be clinically relevant, because they were either
reported as pathogenic/likely pathogenic or as a VUS by different
clinical laboratories. In this regard, CHEK2, PALB2, and BRIP1
were most frequently identified as having discordant interpretation
between these two levels of pathogenicity. As these genes are being
incorporated into clinical practice as part of cancer risk assessment,
tailored screening and cancer prevention recommendations, or
within tumor panel sequencing for potential targeted therapy, it
will be critical to standardize their curation and clinical classifi-
cation of variants to provide appropriate management for mu-
tation carriers and their families.
A strength of this study is the inclusion of individuals who
underwent testing at laboratories that do not submit data to
ClinVar. Our data highlight several specific variants of interest
related to differential reporting. Of 117 of the CHEK2 findings
reported in PROMPT to date, 41 (35%) were conflicting. The
c.470T.C (p.Ile157Thr, I157K) and the c.1283C.T (p.Ser428Phe,
S428F) variants were the most common with conflicting in-
terpretation between pathogenic/likely pathogenic and VUS. The
putative pathogenicity of I157T has long been studied. Several
Assessed for eligibility for PROMPT
(N = 1,191)
Total excluded participants                (n = 112)
  BRCA1/2 findings only                     (n = 100)
  Somatic findings only                          (n = 3)
  No findings on germline test reports  (n= 3)
  Single site testing                                (n = 6)
Participants                                          (n = 669)
Findings                                                (n = 736)
Total with multiple submissions
Participants                                          (n = 518)
Findings                                                (n = 603)
Excluded if only one verified report and, 
therefore, no comparison available
Participants                                       (n = 151)
Findings                                            (n = 197)
Assessed verified data
(n = 1,079)
Total excluded                                    (n = 410)
  Patient-reported findings (gene and 
  variant provided) not in ClinVar   (n = 111)
  Incomplete information provided   (n = 299)
Total with verifiable data (test report directly 
reviewed or patient-reported finding 
present in ClinVar)
Fig 1. CONSORT diagram showing the
flow of participants and genetic variants per
participant from the PROMPT registry until
inclusion for current analysis. PROMPT,
Prospective Registry of Multiplex Testing.
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reports analyze its association with breast cancer risk or other
tumors.9-13 Functional analyses of this variant have also been
published14-16 and in silico predictions are available. The frequency
of this variant in the population is 0.4% in the National Heart,
Lung, and Blood Institute Exome Variant Server and approxi-
mately 5% are found in some Northern European populations.9
Despite these data, there was discordant interpretation of this
evidence by the different clinical genetic laboratories. For instance,
two laboratories found the functional analysis data compelling
enough to suggest a damaging effect on protein function and to
influence variant interpretation, whereas two other laboratories felt
that this variant had no effect on CHEK2 protein kinase activity
and the relationship between functional studies and cancer as-
sociation is unclear. Only one laboratory supported the association
with cancer risk as being significant, whereas the other three
laboratories reported an increased prevalence in affected in-
dividuals, but also documented high frequencies observed among
controls in diverse populations. All agreed that the CHEK2 variant
is located in a well-established functional domain, but only one
laboratory used the supporting limited evidence provided from
predictions of in silico algorithms of this variant’s effect. Overall,
these discrepancies in interpretation of the evidence lead to a range
of clinical interpretations from VUS to pathogenic (low pene-
trance), likely pathogenic, and pathogenic (Table 3).
Differences in interpretation of the evidence for the pathoge-
nicity of CHEK2 S428F are less pronounced but still lead to con-
flicting reports of pathogenic, pathogenic/low penetrance, and VUS.
All laboratories agree that the S428F variant is located in a well-
established functional domain16; and all but one agree that there
is evidence of an increased prevalence in affected individuals v
controls.9 However, three laboratories report that functional
studies are supportive of the damaging effect of CHEK2 S428F,
and one laboratory concludes that the impairment is variable.
Finally, two laboratories report the literature evidence from
cosegregation of the CHEK2 variant with the disease; only one
laboratory reports the prediction of pathogenicity by in silico
algorithms, and another laboratory emphasizes the contribution
of this variant to tumorigenesis by loss of heterozygosity (Table 3).
The examples of the discrepancies involving CHEK2 I157T and
S428F also may reflect the challenges of describing a so-called low-
penetrance susceptibility allele (RR , 2) in a format designed for
high-penetrance alleles.17
Another interesting variant with conflicting interpretation
between likely pathogenic and VUS is the c.139C.G substitution
(p.Pro47Ala) in the BRIP1 gene, which was observed in two un-
related participants from PROMPT. This variant was first described
in 2001,18 when the BRIP1 protein was found to interact with
BRCA1 and contribute to its DNA repair function. This variant was
initially identified in an individual with early-onset breast cancer
and a family history of breast and ovarian cancer; segregation
analysis was not available and loss of heterozygosity in the tumor
was not demonstrated. Since then, it has been reported in the
literature several times as a breast or ovarian cancer susceptibility
gene in affected individuals, but has also been observed in control
subjects.19,20 Two clinical laboratories providing a summary of
their clinical interpretation in ClinVar differ in their assessment of
the meaning of loss of function observed in the experimental
studies in regard to cancer susceptibility; one laboratory highlights
that it is present in population databases, albeit as a very rare allele
(0.04%); and only one endorses the supporting evidence provided
by the prediction of in silico algorithms. In phase 2 of the PROMPT
project, enrollment of family members will be encouraged and
cosegregation analysis of this BRIP1 variant may be undertaken,
which may help provide one more piece of supporting evidence to
clarify its pathogenicity.
Findings of discordant interpretation of results in genetic
testing are not limited to oncologic settings nor ClinVar. Similar
discrepancies also have been observed in hereditary connective-
tissue disorders and are felt to be due to lack of submission of data
to public databases, limited use of allele frequency data, and
varying consideration of protein structure and function.3 In the
current study, the discrepancies between commercial laboratories
in interpretation of variants in cancer-related genes seem to be
mostly based on differences in the interpretation of evidence.
Efforts have already been initiated among laboratories to resolve
these differences.21 The lack of a gold standard test for pathoge-
nicity, or a noncontroversial interpretation of functional analyses,
suggests that discrepant interpretation of challenging variants,
particularly missense and splice-site variants, will persist for
some time.
Table 1. Study Population Enrolled in the Prospective Registry of Multiplex
Testing Registry
Cohort
Eligibility,
No. (%)
Final Cohort,
No. (%)
No. (%) 1,191 518
Median age, (range), years 52 (43-60) 52 (44-61)
Sex
Male 59 (5) 27 (5)
Female 1,111 (93) 491 (95)
Unknown 21 (2) —
Race, no. (%)
Black 10 (0.8) 4 (0.77)
Asian 29 (2) 7 (1)
White 824 (69) 427 (82)
Multiple 45 (4) 22 (4)
Other/unknown 283 (24) 58 (11)
Cancer
Yes 774 (65) 350 (68)
No 363 (30) 162 (31)
Unknown 54 (5) 6 (1)
Cancer diagnoses
Blood/lymphoma 4 (0.5) 4 (1)
Brain 1 (0.1) 1 (0.2)
Breast 397 (51) 188 (54)
Cervical/uterine 15 (2) 7 (2)
Ovarian/fallopian tube 50 (6) 21 (6)
Colon/rectal 25 (3) 7 (2)
Kidney/renal pelvis 2 (0.3) 1 (0.2)
Melanoma 8 (1) 1 (0.2)
Nonmelanoma skin 11 (1) 4 (1)
Pancreas 3 (0.4) 1 (0.2)
Prostate 6 (0.8) 4 (1)
Thyroid 8 (1) 2 (0.4)
Multiple primaries 232 (30) 108 (31)
Not specified/other 12 (1) 1 (0.2)
Referral source
Family/friend 14 (1) 4 (0.77)
Professional/laboratory 775 (65) 419 (81)
Social media/Susan Love Foundation 45 (4) 6 (1)
Online/Internet 18 (2) 7 (1)
Other/unsure/no response 339 (28) 82 (16)
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Multigene testing for cancer susceptibility is a complex en-
deavor characterized by challenges in curation and reporting of
variants; unfortunately, this study demonstrates that conflicting
interpretation of those variants may be relatively frequent. The
rates of discrepant interpretation reported herein support the need
for initiatives focused on harmonizing variant interpretation in the
context of shared data. We encourage clinical laboratories to
submit their findings to ClinVar and other public databases with
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Table 2. Genetic Variants With Conflicting Interpretation
Between Pathogenic/Likely Pathogenic and Uncertain Significance (n = 57)
Gene No. With Multiple Submissions Total No. (%) Description of Variants (No. identified) Type of Variant
APC 10 4 (40) c.3920T.A (p.Ile1307Lys) (2) Missense
c.1240C.T (p.Arg414Cys) (2) Missense
BRIP1 33 2 (6) c.139C.G (p.Pro47Ala) (2) Missense
CDKN2A 5 2 (40) c.9_32dup24 (2) (p.
Pro11_Ser12insAlaAlaGlySerSerMetGluPro)
Duplication
CHEK2 117 36 (31) c.470T.C (p.Ile157Thr) (18) Missense
c.1283C.T (p.Ser428Phe) (12) Missense
c.190G.A (p.Glu64Lys) (2) Missense
c.1111C.T (p.His371Tyr) Missense
c.1427C.T (p.Thr476Met) Missense
c.483_485delAGA (p.Glu161del) Deletion
c.715G.A (p.Glu239Lys) Missense
FH 1 1 c.1431_1433dupAAA (p.Lys477_Asn478insLys) Duplication
MSH6 20 1 (5) c.2927G.A (p.Arg976His) Missense
MUTYH 22 3 (14) c.821G.A (p.Arg274Gln) Missense
c.934-2A.G (2) Splice acceptor
NBN 20 4 (20) c.511A.G (p.Ile171Val) (2) Missense
c.643C.T (p.Arg215Trp) (2) Missense
PALB2 49 3 (6) c.3113G.A (p.Trp1038Ter) (3) Nonsense
RAD51C 26 1 (4) c.1026+5_1026+7delGTA Deletion
Between Benign/Likely Benign and Uncertain Significance (n = 99)
APC 10 2 (20) c.3352A.G (p.Asn1118Asp) Missense
c.6821C.T (p.Ala2274Val) Missense
ATM 105 32 (30) c.1229T.C (p.Val410Ala) (7) Missense
c.4388T.G (p.Phe1463Cys) (6) Missense
c.6067G.A (p.Gly2023Arg) (5) Missense
c.1810C.T(p.Pro604ser) (4) Missense
c.2932T.C (p.Ser978Pro) (2) Missense
c.4424A.G (p.Tyr1475Cys) (2) Missense
c.1066-6T.G (IVS8-6 T.G) Missense
c.1073A.G (p.Asn358Ser) Missense
c.3925G.A (p.Ala1309Thr) Missense
c.4709T.C (p.Val1570Ala) Missense
c.7390T.C (p.Cys2464Arg) Missense
c.8734A.G (p.Arg2912Gly) Missense
BARD1 23 8 (35) c.2282G.A (p.Ser761Asn) (4) Missense
c.33G.T (p.Gln11His) Missense
c.1694G.A (p.Arg565His) Missense
c.1977A.G (p.Arg659 = ) Synonymous
c.2191C.G (p.Arg731Gly) Missense
BMPR1A 2 2 (100) c.1243G.A (p.Glu415Lys) Missense
c.1327C.T (p.Arg443Cys) Missense
BRCA2 23 3 (12) c.6803G.A (p.Arg2268Lys) Missense
c.10121C.T(p.Thr3374lle) Missense
c.1514T.C (p.Ile505Thr) Missense
BRIP1 33 1 (3) c.587A.G (p.Asn196Ser) Missense
CDH1 19 2 (10) c.670C.T (p.Arg224Cys) Missense
c.1774G.A (p.Ala592Thr) Missense
CDKN2A 5 1 (20) c.361G.A (p.Ala121Thr) Missense
CHEK2 117 5 (4) c.320-5T.A (2) Intron variant
c.538C.T (p.Arg180Cys) (2) Missense
c.707T.C (p.Leu236Pro) Missense
FANCC 3 3 (100) c.345+6A.T Intron variant
c.632C.G (p.Pro211Arg) Missense
c.178G.A (p.Val60Ile) Missense
MLH1 7 1 (17) c.2252A.G (p.Lys751Arg) Missense
MRE11A 8 2 (25) c.1475C.A (p.Ala492Asp) (2) Missense
MUTYH 22 1 (4) c.1276C.T (p.Arg426Cys) Missense
NBN 20 2 (10) c.1720T.A (p.Leu574Ile) (2) Missense
NF1 4 1 (25) c.8041A.G (p.Ile2681Val) Missense
PALB2 49 6 (12) c.2228A.G (p.Tyr743Cys) Missense
c.2816T.G (p.Leu939Trp) (3) Missense
c.656A.G (p.Asp219Gly) (2) Missense
PMS2 21 4 (19) c.86G.C (p.Gly29Ala) (2) Missense
c.620G.A (p.Gly207Glu) (2) Missense
(continued on following page)
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relevant clinical interpretations of findings, as well as the evidence
on which interpretations are based. To better identify the un-
derlying reasons for their discrepant interpretation, laboratories
could explicitly describe their weighting (from very strong to
moderate or supporting) for each pathogenic criterion used for
classification.6 This transparency in data sharing and collaboration
between academic research consortia and commercial laboratories
may promote strategies to standardize clinical variant curation
algorithms. Ongoing consortia such as Evidence-Based Network
for the Interpretation of Germline Mutant Alleles (ENIGMA), and
International Society for Gastrointestinal Hereditary Tumors (In-
SIGHT) have demonstrated the utility of multidisciplinary collabo-
ration to curate and reclassify submitted VUS.22,23 Platforms such as
the Leiden Open Source Variation Database (LOVD)24, which allows
for collection, curation, and display of phenotypes and DNA sequence
variants, and the BRCA Challenge (http://brcaexchange.org/; an in-
ternational effort to review and provide vetted data on BRCA1 and
BRCA2 gene variants) are additional relevant resources. PROMPTuses
Table 2. Genetic Variants With Conflicting Interpretation (continued)
Between Benign/Likely Benign and Uncertain Significance (n = 99)
Gene No. With Multiple Submissions Total No. (%) Description of Variants (No. identified) Type of Variant
RAD50 17 4 (24) c.3036+5G.A (3) Missense
c.943G.T (p.Val315Leu) Missense
RAD51C 26 12 (46) c.790G.A (p.Gly264Ser) (12) Missense
STK11 2 1 c.1211c.T (p.Ser404Phe) Missense
TP53 15 5 (33) c.248C.T (p.Ala83Val) Missense
c.704A.G (p.Asn235Ser) Missense
TSC2 1 1 (100) c.5378G.A (p.Arg1793Gln) Missense
Table 3. Criteria Used for Clinical Interpretation of CHEK2 Variants p.S428F and p.I157K
Criteria for Classifying Pathogenic Variants Laboratory 1 Laboratory 2 Laboratory 3 Laboratory 4
CHEK2 p.S428F
Functional studies, from literature review,
supportive of a damaging effect(very
strong evidence)
x x x x*
Increased prevalence in affected individuals v
control subjects (strong evidence)
x x x x†
Location in a well-established functional
domain (moderate evidence)
x x x x
Cosegregation with disease in multiple
affected family members (supporting
evidence)
N/A x x N/A
Prediction by in silico algorithms (supporting
evidence)
x N/A N/A N/A
Contribution to tumorigenesis determined by
LOH
N/A x N/A N/A
Final interpretation Pathogenic Pathogenic
(low penetrance)
Pathogenic Uncertain clinical
significance
CHEK2 p.I157K
Functional studies, from literature review,
supportive of a damaging effect (very
strong evidence)
x x‡ x x‡
Increased prevalence in affected individuals v
control subjects (strong evidence)
x§ x x§ x§
Location in a well-established functional
domain (moderate evidence)
x x x x
Cosegregation with disease in multiple
affected family members (supporting
evidence)
x§ N/A x¶ N/A
Prediction by in silico algorithms (supporting
evidence)
Inconsistent N/A Limited value N/A
Contribution to tumorigenesis determined by
LOH
N/A N/A N/A N/A
Final interpretation Expected
pathogenic
Pathogenic
(low penetrance)
Pathogenic Uncertain clinical
significance
Abbreviations: LOH, loss of heterozygosity; N/A, not applicable.
*Interpretation of variable impairment.
†Interpretation of increased risk only in specific populations.
‡No effect on CHEK2 protein kinase activity, and relationship between experimental findings and cancer association is unclear.
§Observed at high frequencies among controls in some particular populations.
¶Incomplete segregation.
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both crowd-sourcing and direct participant enrollment; therefore, it
also can provide a platform for cohort formation and prospective
follow-up of individuals and their family members harboring genetic
variants. However, at this time, health-care providers and patients
need to be aware that there could be conflicting interpretations of
variants and those variants may be reclassified.
Our analysis has limitations. Because PROMPT is an elective,
patient-oriented registry, there may be significant ascertainment
bias. For example, individuals with VUS or those who were self-
aware of a variant with conflicting interpretation may have been
more likely to report their variant to PROMPT, leading to an
overestimation of discrepant findings. On the other hand, a sig-
nificant number of test results reported by participants were not
submitted to ClinVar by any laboratory and, therefore, were ex-
cluded from the primary analysis, potentially leading to a mis-
estimate of conflicting variant interpretations. Finally, because
some patients did not upload their clinical test report, it was not
possible to carry out more in-depth analysis in many cases. Efforts
to obtain reports from all participants are ongoing.
In conclusion, clinical interpretation of genetic testing for
increased cancer susceptibility as assessed by multiplex panels
hinges on accurate curation and interpretation of variants. Dis-
crepant interpretation of some genetic variants appears to be
common. Internet-based registries provide a powerful tool to
collect data to inform efforts to standardize classification of genetic
variants, and can play an important role in efforts to minimize
potential medical harms due to false alarm or false reassurance
following cancer genetic testing.
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Fig A1. Type of conflicting interpretation by genes.
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